Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 64 of 64 results for etanercept

  1. Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)

    Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.

    Technology appraisal guidance
    Published
    15 April 2025

    Sections for TA1054

  2. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Withdrawn guidance

  3. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.

    Highly specialised technologies guidance
    Published
    5 May 2022
    View recommendations

    Sections for HST20

  4. NICE recommends several treatment options to help with rheumatoid arthritis

    Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.

    News
    Last updated
    17 January 2024